MGO One Seven LLC Acquires 5,202 Shares of Bristol-Myers Squibb (NYSE:BMY)

MGO One Seven LLC increased its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 21.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 29,376 shares of the biopharmaceutical company's stock after purchasing an additional 5,202 shares during the quarter. MGO One Seven LLC's holdings in Bristol-Myers Squibb were worth $1,662,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Transce3nd LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $28,000. Fairway Wealth LLC purchased a new stake in Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Comprehensive Financial Planning Inc. PA purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $34,000. Westend Capital Management LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at $38,000. Finally, Tacita Capital Inc purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at about $39,000. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on BMY. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Truist Financial raised their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Piper Sandler assumed coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price for the company. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb presently has an average rating of "Hold" and a consensus price target of $58.00.

Insider Activity

In related news, EVP Samit Hirawat bought 1,823 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the acquisition, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Up 1.1 %

BMY traded up $0.55 on Monday, reaching $48.45. The company's stock had a trading volume of 18,572,631 shares, compared to its average volume of 12,950,880. The stock has a market cap of $98.58 billion, a price-to-earnings ratio of -10.96, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. The business's 50 day moving average is $56.37 and its 200 day moving average is $56.53. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company's quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the business posted ($4.40) EPS. As a group, research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.12%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.